Cholinergic Treatments of Alzheimer's Disease
作者： Nicholas D. Tsopelas , Deborah B. Marin
DOI: 10.1016/B978-012351830-9/50034-2
关键词:
摘要: This chapter reviews the evidences that support use of therapies targeting cholinergic system. There are several lines suggest a critical role mechanisms involved in Alzheimer's Disease (AD). The conceptualization treatments for AD is accordance with preclinical and basic science findings. Usually, innervations neurotransmission pivotal effective execution complex cognitive tasks. At same time, different deficits can be effectively restored agents. Experimentations cholinergic-rich fetal tissue transplants acetylcholine restoring learning memory by following basal forebrain damage. also discusses fact brains demonstrate no change or an increased number muscarinic receptors, as well decreased high affinity nicotinic receptors. Significant correlation usually exists between severity dementia. All these findings potential therapeutic value agents enhance upgrade AD.
elsevier.com
sci-hub.se 参考文章(191)
Abraham Fisher, Eliahu Heldman, David Gurwitz, Rachel Haring, Yishai Karton, Haim Meshulam, Zippora Pittel, Daniele Marciano, Itzhak Marcovitch, Rachel Brandeis, Terese A. Treves, Ruth Verchovsky, Sonia Klimowsky, Amos D. Korczyn, Selective Signaling Via Novel Muscarinic Agonists: Implications for Alzheimer’s Disease Treatments and Clinical Update Birkhäuser Boston. pp. 219- 223 ,(1994) , 10.1007/978-1-4615-8149-9_37
Meshulam H, Gurwitz D, Heldman E, Karton Y, Pittel Z, Haring R, Marciano D, Fisher A, Brandeis R, Segall Y, Progress in medicinal chemistry of novel selective muscarinic agonists. Drug Design and Discovery. ,vol. 9, pp. 221- 235 ,(1993)
Nordberg A, Neuroreceptor changes in Alzheimer disease. Cerebrovascular and brain metabolism reviews. ,vol. 4, pp. 303- ,(1992)
Jennifer T. Coull, Pharmacological Manipulations of the ??2-Noradrenergic System Drugs & Aging. ,vol. 5, pp. 116- 126 ,(1994) , 10.2165/00002512-199405020-00005
DA Cozanitis, T Friedmann, S Fürst, Study of the analgesic effects of galanthamine, a cholinesterase inhibitor. Archives internationales de pharmacodynamie et de thérapie. ,vol. 266, pp. 229- 238 ,(1983)
Jack E. Riggs, THE "PROTECTIVE" INFLUENCE OF CIGARETTE SMOKING ON ALZHEIMER'S AND PARKINSON'S DISEASES Quagmire or Opportunity for Neuroepidemiology? Neurologic Clinics. ,vol. 14, pp. 353- 358 ,(1996) , 10.1016/S0733-8619(05)70261-9
Shun Shimohama, Takashi Taniguchi, Motohatsu Fujiwara, Masakuni Kameyama, Changes in Nicotinic and Muscarinic Cholinergic Receptors in Alzheimer-Type Dementia Journal of Neurochemistry. ,vol. 46, pp. 288- 293 ,(1986) , 10.1111/J.1471-4159.1986.TB12960.X
Ian G. McKeith, The Clinical Trial Protocol of the Metrifonate in ALzheimer’s Trial (MALT) Dementia and Geriatric Cognitive Disorders. ,vol. 9, pp. 2- 7 ,(1998) , 10.1159/000051192
A. Fisher, R. Brandeis, Z. Pittel, I. Karton, M. Sapir, S. Dachir, A. Levy, E. Heldman, (±)-cis-2-Methyl-spiro(1,3-oxathiolane-5,3′) quinuclidine (AF102B): A new M1 agonist attenuates cognitive dysfunctions in AF64A-treated rats Neuroscience Letters. ,vol. 102, pp. 325- 331 ,(1989) , 10.1016/0304-3940(89)90100-6
Deborah B. Marin, Linda M. Bierer, Brian A. Lawlor, Theresa M. Ryan, Rachel Jacobson, James Schmeidler, Richard C. Mohs, Kenneth L. Davis, L-deprenyl and physostigmine for the treatment of Alzheimer's disease. Psychiatry Research-neuroimaging. ,vol. 58, pp. 181- 189 ,(1995) , 10.1016/0165-1781(95)02714-8